Study of Durvalumab following radiation therapy in patients with stage 3 unresectable NSCLC ineligible for chemotherapy

Trial Identifier: D4194C00009
Sponsor: AstraZeneca
NCTID:: NCT04249362
Start Date: November 2020
Primary Completion Date: March 2023
Study Completion Date: November 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
French Translation
Italian Translation
Polish Translation
Russian Translation

Trial Locations

Country Location
ES A Coru�a, ES, 15006
ES Barcelona, ES, 8035
ES Castello de la Plana, ES, 12002
ES Madrid, ES, 28050
ES Oviedo, ES, 33011
ES Pamplona, ES, 31008
ES Sabadell(Barcelona), ES, 08208
FR Limoges, FR, 87000
FR Marseille, FR, 13009
FR Montpellier, FR, 34070
FR Nimes, FR, 30029
FR ROUEN, FR, 76031
IT Brescia, IT, 25100
IT Firenze, IT, 50134
IT Genova, IT, 16132
IT Meldola, IT, 47014
IT Messina, IT, 98158
IT Modena, IT, 41124
IT Monza, IT, 20900
IT Negrar, IT, 37024
IT Pavia, IT, 27100
IT PISA, IT, 56124
IT Ravenna, IT, 48121
IT Roma, IT, 00128
PL Bialystok, PL, 15-044
PL Gdansk, PL, 80-214
PL Olsztyn, PL, 10-228
PL Szczecin, PL, 71-730
PL Warszawa, PL, 02-781
RU St. Petersburg, RU, 197758
RU St. Petersburg, RU, 197002
RU Ufa, RU, 450054
US, AZ Tucson, AZ, US, 85704
US, FL Tampa, FL, US, 33612
US, MI Royal Oak, MI, US, 48073